Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Feb 06, 2024 7:49am
135 Views
Post# 35864788

RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsAre you actually suggesting BMS is going to offer 10 Biillion to acquire ONCY..??  If their sweet spot is 10B+, doesn't that actually exclude ONCY... what is the company worth now... oh yes, around 64 million + 20 million cash ?? 64 million for two phase III "ready" assets... even though one of those indications has been phase III ready for almost 6 years, and has been waiting at the alter for a would be suitor to arrive... 

so tell us WHY BMS would offer 10B for our dog and pony show, rather than just wait for our patents to expire in a few years, and use Pela themselves.?

NONE of your 4 years of posting about buyouts / acquisitions by Big Pharma have come to fruition, well actually they have, just not in ONCY's favor...

IN fact, ONCY's doors have been open to patrners tor 10 years, and the closest they came was with Adlai Nortye, who themselve have never brought a product to market... way to go ONCY.

it seems clear that anyone who posts as much unrelated fluff as you do, and who tries to pass it off as fact, must be on ONCY's payroll.
<< Previous
Bullboard Posts
Next >>